ReviewEndocrine reviews2019
Targeted Therapy for Advanced Thyroid Cancer: Kinase Inhibitors and Beyond.
Review in Endocrine reviews, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 207 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
207 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Association of radiomic features with genomic signatures in thyroid cancer: a systematic review.Journal of translational medicine · 2024Pooled it
- Preoperative molecular testing in thyroid nodules with Bethesda VI cytology: Clinical experience and review of the literature.Diagnostic cytopathology · 2021Pooled it
- Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study.Annals of oncology : official journal of the European Society for Medical Oncology · 2022Trial
- Intensity-modulated radiation therapy and doxorubicin in thyroid cancer: A prospective phase 2 trial.Cancer · 2021Trial
- Photon irradiation prompts autophagy in anaplastic thyroid cancer.BMC cancer · 2026Article
- Advances in Optical and Fluorescence Imaging for Surgical Management of Thyroid Cancer.Cancers · 2026Review
- Article
- Complete response of lymph node metastasis following adjuvant dabrafenib and trametinib treatment for BRAF V600-mutant anaplastic thyroid cancer - case report.International journal of surgery case reports · 2026Article
- Mechanism of and research progress on alterations in the RET gene in thyroid cancer (Review).Molecular medicine reports · 2026Review
- Astragaloside IV Reduces Sorafenib-Induced Cardiotoxicity by Inhibiting Apoptosis Through the STAT3/HIF-1α/Bcl-2 Signaling Pathway.International journal of molecular sciences · 2026Article
- Lenvatinib in radioiodine-refractory differentiated thyroid cancer: a real-world institutional analysis.Endocrine journal · 2026Article
- Molecular Determinants of Thyroid Cancer Progression: Thyroid Hormone Signaling, the BRAF/MAPK Pathway, and Emerging miRNA Biomarkers.Biomedicines · 2026Review
- Positive prognostic implications of SPHK1 expression in patients with papillary thyroid carcinoma undergoing radioactive iodine therapy.Scientific reports · 2026Article
- Nanocarriers, Smart Biomaterials and Emerging Therapeutics for Psoriasis: Current Progress and Future Directions.AAPS PharmSciTech · 2026Review
- Fatal tracheal perforation following Dabrafenib-Trametinib therapy inJCEM case reports · 2026Article
- Microfluidic-based patient-derived organoids recapitulate thyroid cancer heterogeneity and reveal NF-κB-driven maturation for precision therapy.Journal of translational medicine · 2026Article
- Therapeutic Potential of Tyrosine Kinase Inhibitors in Advanced Thyroid Cancer.Current oncology reports · 2026Review
- The dual axis of tumorigenesis: MAPK and PI3K/AKT pathways in papillary thyroid carcinoma.Oncoscience · 2026Article
- Modeling the Effects of Single Nucleotide Polymorphisms (SNPs) on the Structure and Function of the HumanHuman mutation · 2026Article
- Superior efficacy of vemurafenib combined with iodine-131 for lymph node metastatic BRAF-mutant thyroid cancer: a long-term survival analysis.American journal of translational research · 2026Article
147 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The treatment of advanced thyroid cancer has undergone rapid evolution in the last decade, with multiple kinase inhibitor drug approvals for each subtype of thyroid cancer and a number of other commercially available drugs that have been studied for this indication. Although most of the US Food and Drug Administration (FDA)-approved drugs are antiangiogenic multikinase inhibitors-vandetanib, cabozantinib, sorafenib, lenvatinib-there are two FDA indications that are mutation specific-dabrafenib/trametinib for BRAF-mutated anaplastic thyroid cancer and larotrectinib for NTRK-fusion thyroid cancer. Furthermore, other mutation-specific drugs, immunotherapies, and novel strategies for advanced thyroid cancer are under investigation. Understanding the molecular basis of thyroid cancer, the drugs of interest for treatment of advanced thyroid cancer, and how these drugs can be administered safely and in the appropriate clinical scenario are the topics of this review.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.